CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management

References

• Surveillance, Epidemiology, and End Results (SEER) Program. SEER*stat database: statistics at a Glance: stomach cancer. Available From: http://www.seer.cancer.gov. Accessed 713, 2019.
   Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49. doi:10.1111/apm.1965.64.1.3114320675
   PubMedGoogle Scholar
• Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumors of the Digestive System. Lyon: International Agency for research on Cancer; 2010:48–58.
   Google Scholar
• Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392(6674):402–405. doi:10.1038/329189537325
   PubMed Web of Science ®Google Scholar
• Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58(18):4086–4089.9751616
   PubMed Web of Science ®Google Scholar
• Corso G, Intra M, Trentin C, Veronesi P, Galimberti V. CDH1 germline mutations and hereditary lobular breast cancer. Fam Cancer. 2016;15(2):215–219. doi:10.1007/s10689-016-9869-526759166
   PubMed Web of Science ®Google Scholar
• Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54(14):3845–3852.8033105
   PubMed Web of Science ®Google Scholar
• Gall TM, Frampton AE. Gene of the month: E-cadherin (CDH1). J Clin Pathol. 2013;66(11):928–932. doi:10.1136/jclinpath-2013-20176823940132
   PubMed Web of Science ®Google Scholar
• Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol. 2001;153(5):1049–1060. doi:10.1083/jcb.153.5.104911381089
   PubMed Web of Science ®Google Scholar
• Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27(55):6920–6929. doi:10.1038/onc.2008.34319029934
   PubMed Web of Science ®Google Scholar
• Kourtidis A, Ngok SP, Anastasiadis PZ. p120 catenin: an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression. Prog Mol Biol Transl Sci. 2013;116:409–432.23481205
   PubMed Web of Science ®Google Scholar
• Bruner HC, Derksen PWB. Loss of E-Cadherin-dependent cell-cell adhesion and the development and progression of cancer. Cold Spring Harb Perspect Biol. 2018;10(3):a029330. doi:10.1101/cshperspect.a02933028507022
   PubMed Web of Science ®Google Scholar
• Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303(5663):1483–1487. doi:10.1126/science.109429115001769
   PubMed Web of Science ®Google Scholar
• Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–829. doi:10.1016/j.devcel.2008.05.00918539112
   PubMed Web of Science ®Google Scholar
• Li D, Lo W, Rudloff U. Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin-EGFR crosstalk. Clin Transl Med. 2018;7(1):7. doi:10.1186/s40169-018-0184-729468433
   PubMedGoogle Scholar
• Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004;23(8):1739–1748. doi:10.1038/sj.emboj.760013615057284
   PubMed Web of Science ®Google Scholar
• Bremm A, Walch A, Fuchs M, et al. Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. Cancer Res. 2008;68(3):707–714. doi:10.1158/0008-5472.CAN-07-158818245470
   PubMed Web of Science ®Google Scholar
• Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645–3654. doi:10.1158/0008-5472.CAN-07-293818483246
   PubMed Web of Science ®Google Scholar
• Figueiredo J, Melo S, Carneiro P, et al. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet. 2019;56(4):199–208. doi:10.1136/jmedgenet-2018-10580730661051
   PubMed Web of Science ®Google Scholar
• Perrais M, Chen X, Perez-Moreno M, Gumbiner BM. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell. 2007;18(6):2013–2025. doi:10.1091/mbc.e06-04-034817392517
   PubMed Web of Science ®Google Scholar
• Tan P, Yeoh KG. Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology. 2015;149(5):1153–1162. doi:10.1053/j.gastro.2015.05.05926073375
   PubMed Web of Science ®Google Scholar
• Nam S, Kim JH, Lee DH. RHOA in gastric cancer: functional roles and therapeutic potential. Front Genet. 2019;10:438. doi:10.3389/fgene.2019.0043831156701
   PubMed Web of Science ®Google Scholar
• Cowell CF, Yan IK, Eiseler T, Leightner AC, Döppler H, Storz P. Loss of cell-cell contacts induces NF-kappaB via RhoA-mediated activation of protein kinase D1. J Cell Biochem. 2009;106(4):714–728. doi:10.1002/jcb.2206719173301
   PubMed Web of Science ®Google Scholar
• Cano A, Pérez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2(2):76–83. doi:10.1038/3500002510655586
   PubMed Web of Science ®Google Scholar
• Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009;1(6):a003129. doi:10.1101/cshperspect.a00312920457567
   PubMed Web of Science ®Google Scholar
• Carneiro P, Fernandes MS, Figueiredo J, Caldeira J, et al. E-cadherin dysfunction in gastric cancer–cellular consequences, clinical applications and open questions. FEBS Lett. 2012;586(18):2981–2989. doi:10.1016/j.febslet.2012.07.04522841718
   PubMed Web of Science ®Google Scholar
• Adam AJ, Thorsson V, Shmulevich I; Cancer genome atlas research network, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209.25079317
   PubMed Web of Science ®Google Scholar
• Ushiku T, Ishikawa S, Kakiuchi M, et al. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases. Gastric Cancer. 2016;19(2):403–411. doi:10.1007/s10120-015-0493-025823974
   PubMed Web of Science ®Google Scholar
• Schrader KA, Masciari S, Boyd N, et al. Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer. 2008;7(1):73–82.18046629
   PubMed Web of Science ®Google Scholar
• Suriano G, Oliveira C, Ferreira P, et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet. 2003;12(5):575–582. doi:10.1093/hmg/ddg04812588804
   PubMed Web of Science ®Google Scholar
• Lynch HT, Silva E, Wirtzfeld D, Hebbard P, Lynch J, Huntsman DG. Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin N Am. 2008;88(4):759–778. doi:10.1016/j.suc.2008.04.00618672140
   PubMed Web of Science ®Google Scholar
• Barber M, Murrell A, Ito Y, et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol. 2008;216(3):295–306. doi:10.1002/path.242618788075
   PubMed Web of Science ®Google Scholar
• Oliveira C, Sousa S, Pinheiro H, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology. 2009;136(7):2137–2148. doi:10.1053/j.gastro.2009.02.06519269290
   PubMed Web of Science ®Google Scholar
• Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet. 2000;26(1):16–17. doi:10.1038/7912010973239
   PubMed Web of Science ®Google Scholar
• Melo S, Figueiredo J, Fernandes MS, et al. Predicting the functional impact of CDH1 Missense mutations in hereditary diffuse gastric cancer. Int J Mol Sci. 2017;18:12. doi:10.3390/ijms18122687
   Web of Science ®Google Scholar
• Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery. 2001;130(4):612–617.11602891
   PubMed Web of Science ®Google Scholar
• Guilford P, Blair V, More H, Humar B. A short guide to hereditary diffuse gastric cancer. Hered Cancer Clin Pract. 2007;5(4):183–194. doi:10.1186/1897-4287-5-4-18319725995
   PubMed Web of Science ®Google Scholar
• Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer. 2008;112(12):2655–2663.18442100
   PubMed Web of Science ®Google Scholar
• Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32. doi:10.1001/jamaoncol.2014.16826182300
   PubMed Web of Science ®Google Scholar
• Pharoah PD, Guilford P, Caldas C; International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–1353. doi:10.1053/gast.2001.2961111729114
   PubMed Web of Science ®Google Scholar
• Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41(7):508–517. doi:10.1136/jmg.2004.01827515235021
   PubMed Web of Science ®Google Scholar
• Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155(2):337–342. doi:10.1016/S0002-9440(10)65129-210433926
   PubMed Web of Science ®Google Scholar
• van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–374. doi:10.1136/jmedgenet-2015-10309425979631
   PubMed Web of Science ®Google Scholar
• Fewings E, Larionov A, Redman J, et al. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol Hepatol. 2018;3(7):489–498. doi:10.1016/S2468-1253(18)30079-729706558
   PubMed Web of Science ®Google Scholar
• Carvalho S, Catarino TA, Dias AM, et al. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene. 2016;35(13):1619–1631. doi:10.1038/onc.2015.22526189796
   PubMed Web of Science ®Google Scholar
• Ansari S, Gantuya B, Tuan VP, Yamaoka Y. Diffuse gastric cancer: a summary of analogous contributing factors for its molecular pathogenicity. Int J Mol Sci. 2018;19:8.
   Web of Science ®Google Scholar
• Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germline E-cadherin mutations. NEJM. 2001;344(25):1904–1909. doi:10.1056/NEJM20010621344250411419427
   PubMed Web of Science ®Google Scholar
• Fitzgerald RC, Hardwick R, Huntsman D; International Gastric Cancer Linkage Consortium, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436–444. doi:10.1136/jmg.2009.07423720591882
   PubMed Web of Science ®Google Scholar
• Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–262. doi:10.1038/ajg.2014.43525645574
   PubMed Web of Science ®Google Scholar
• Kumar S, Long JM, Ginsberg GG, Katona BW. The role of endoscopy in the management of hereditary diffuse gastric cancer syndrome. World J Gastroenterol. 2019;25(23):2878–2886. doi:10.3748/wjg.v25.i23.287831249446
   PubMed Web of Science ®Google Scholar
• van Kouwen MC, Drenth JP, Oyen WJ, et al. [18F] Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res. 2004;10(19):6456–6459. doi:10.1158/1078-0432.CCR-04-059915475432
   PubMed Web of Science ®Google Scholar
• Dossus L, Benusiglio PR. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res. 2015;17:37. doi:10.1186/s13058-015-0546-725848941
   PubMed Web of Science ®Google Scholar
• Knuttel FM, Menezes GL, van den Bosch MA, Gilhuijs KG, Peters NH. Current clinical indications for magnetic resonance imaging of the breast. J Surg Oncol. 2014;110(1):26–31. doi:10.1002/jso.2365524861355
   PubMed Web of Science ®Google Scholar
• Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245(6):873–879. doi:10.1097/01.sla.0000254370.29893.e417522512
   PubMed Web of Science ®Google Scholar
• Rocha JP, Gullo I, Wen X, et al. Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. Histopathology. 2018;73(6):878–886.30014492
   PubMed Web of Science ®Google Scholar
• Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4(3):262–275. doi:10.1016/j.cgh.2005.12.00316527687
   PubMed Web of Science ®Google Scholar
• Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg. 2006;202(4):612–617. doi:10.1016/j.jamcollsurg.2005.12.01716571431
   PubMed Web of Science ®Google Scholar
• Hackenson D, Edelman DA, McGuire T, Weaver DW, Webber JD. Prophylactic laparoscopic gastrectomy for hereditary diffuse gastric cancer: a case series in a single family. JSLS. 2010;14(3):348–352. doi:10.4293/108680810X1292446600744921333186
   PubMed Web of Science ®Google Scholar
• Haverkamp L, van der Sluis PC, Ausems MG, et al. Prophylactic laparoscopic total gastrectomy with Jejunal pouch reconstruction in patients carrying a CDH1 germline mutation. J Gastrointest Surg. 2015;19(12):2120–2125. doi:10.1007/s11605-015-2963-426443527
   PubMed Web of Science ®Google Scholar
• Hyodo M, Hosoya Y, Hirashima Y, et al. Minimum leakage rate (0.5%) of stapled esophagojejunostomy with sacrifice of a small part of the jejunum after total gastrectomy in 390 consecutive patients. Dig Sur. 2007;24(3):169–172. doi:10.1159/000102100
   PubMed Web of Science ®Google Scholar
• Schmidt B, Yoon SS. D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol. 2013;107(3):259–264. doi:10.1002/jso.2312722513454
   PubMed Web of Science ®Google Scholar
• Pantelis D, Hüneburg R, Adam R, et al. Prophylactic total gastrectomy in the management of hereditary tumor syndromes. Int J Colorectal Dis. 2016;31(12):1825–1833. doi:10.1007/s00384-016-2656-927682646
   PubMed Web of Science ®Google Scholar
• Worster E, Liu X, Richardson S, et al. The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. Ann Surg. 2014;260(1):87–93. doi:10.1097/SLA.000000000000044624424140
   PubMed Web of Science ®Google Scholar
• Muir J, Aronson M, Esplen MJ, Pollett A, Swallow CJ. Prophylactic total gastrectomy: a prospective cohort study of long-term impact on quality of life. J Gastrointest Surg. 2016;20(12):1950–1958. doi:10.1007/s11605-016-3287-827752808
   PubMed Web of Science ®Google Scholar
• Kaurah P, Talhouk A, MacMillan A, et al. Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery. Fam Cancer. 2019. doi:10.1007/s10689-019-00133-9
   PubMed Web of Science ®Google Scholar
• Wu CW, Chio JM, Ko FS, et al. Quality of life after curative gastrectomy for gastric cancer in a randomized controlled trial. Br J Cancer. 2008;98:54–59. doi:10.1038/sj.bjc.660409718182977
   PubMed Web of Science ®Google Scholar
• Buhl K, Lehnert T, Schlag P, Herfarth C. Reconstruction after gastrectomy and quality of life. World J Surg. 1995;19(4):558–564. doi:10.1007/BF002947227676700
   PubMed Web of Science ®Google Scholar
• Hebbard PC, Macmillan A, Huntsman D, et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol. 2009;16(7):1890–1895. doi:10.1245/s10434-009-0471-z19408054
   PubMed Web of Science ®Google Scholar
• Hallowell N, Lawton J, Badger S, et al. The psychosocial impact of undergoing Prophylactic Total Gastrectomy (PTG) to manage the risk of Hereditary Diffuse Gastric Cancer (HDGC). J Genet Couns. 2017;26(4):752–762. doi:10.1007/s10897-016-0045-827837291
   PubMed Web of Science ®Google Scholar
• Kaurah P, Fitzgerald R, Dwerryhouse S, Huntsman DG. Pregnancy after prophylactic total gastrectomy. Fam Cancer. 2010;9(3):331–334. doi:10.1007/s10689-009-9316-y20063069
   PubMed Web of Science ®Google Scholar
• Simpson JL. Preimplantation genetic diagnosis at 20 years. Prenat Diagn. 2010;30(7):682–695. doi:10.1002/pd.v30:720572111
   PubMed Web of Science ®Google Scholar